Literature DB >> 31970446

Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study.

Nathalie Van Aerde1, Philippe Meersseman2, Yves Debaveye1,3, Alexander Wilmer2, Jan Gunst1,3, Michael P Casaer1,3, Frans Bruyninckx4, Pieter J Wouters1,3, Rik Gosselink5, Greet Van den Berghe1,3, Greet Hermans6,7.   

Abstract

PURPOSE: To assess the independent association between ICU-acquired neuromuscular complications and 5-year mortality and morbidity. To explore the optimal threshold of the Medical Research Council (MRC) sum score, assessing weakness, for the prediction of 5-year outcomes.
METHODS: Sub-analyses of a prospective, 5-year follow-up study including 883 EPaNIC patients (Early versus Late Parenteral Nutrition in Intensive Care) (Clinicaltrials.gov:NCT00512122), systematically screened in ICU for neuromuscular complications with MRC sum score ('MRC-cohort', N = 600), electrophysiology on day 8 ± 1 to quantify compound muscle action potential ('CMAP-cohort', N = 689), or both ('MRC&CMAP-cohort', N = 415). Associations between ICU-acquired neuromuscular complications and 5-year mortality, hand-grip strength (HGF, %predicted), 6-min-walk distance (6-MWD, %predicted) and physical function of the SF-36 quality-of-life questionnaire (PF-SF-36) at 5-years were assessed with Cox regression and linear regression, adjusted for confounders. The optimal threshold for MRC at ICU discharge to predict 5-year outcomes was determined by martingale residual plots (survival) and scatterplots (morbidity).
RESULTS: Both lower MRC sum score at ICU discharge, indicating less strength [HR, per-point-increase: 0.946 (95% CI 0.928-0.968), p = 0.001], and abnormal CMAP, indicating nerve/muscle dysfunction [HR: 1.568 (95% CI 1.165-2.186), p = 0.004], independently associated with increased 5-year mortality. In the MRC&CMAP-cohort, MRC [HR: 0.956 (95% CI 0.934-0.980), p = 0.001] but not CMAP [HR: 1.478 (95% CI 0.875-2.838), p = 0.088] independently associated with 5-year mortality. Among 205 survivors, low MRC independently associated with low HGF [0.866 (95% CI 0.237-1.527), p = 0.004], low 6-MWD [105.1 (95% CI 12.1-212.9), p = 0.043] and low PF-SF-36 [- 0.119 (95% CI - 0.186 to - 0.057), p = 0.002], whereas abnormal CMAP did not correlate with these morbidity endpoints. Exploratory analyses suggested that MRC ≤ 55 best predicted poor long-term morbidity and mortality. Both MRC ≤ 55 and abnormal CMAP independently associated with 5-year mortality.
CONCLUSIONS: ICU-acquired neuromuscular complications may impact 5-year morbidity and mortality. MRC sum score, even if slightly reduced, may affect long-term mortality, strength, functional capacity and physical function, whereas abnormal CMAP only related to long-term mortality.

Entities:  

Keywords:  Critical care outcomes; Electrophysiology; Muscle weakness; Paresis

Mesh:

Year:  2020        PMID: 31970446     DOI: 10.1007/s00134-020-05927-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  28 in total

1.  Risk Factors for Physical Function Impairments in Postintensive Care Syndrome: A Scoping Review.

Authors:  Min Ding; Chunfeng Yang; Yumei Li
Journal:  Front Pediatr       Date:  2022-06-17       Impact factor: 3.569

2.  Efficacy and safety of ketone ester infusion to prevent muscle weakness in a mouse model of sepsis-induced critical illness.

Authors:  Greet Van den Berghe; Lies Langouche; Ruben Weckx; Chloë Goossens; Sarah Derde; Lies Pauwels; Sarah Vander Perre
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

3.  Support and follow-up needs of patients discharged from intensive care after severe COVID-19: a mixed-methods study of the views of UK general practitioners and intensive care staff during the pandemic's first wave.

Authors:  Ana Cristina Castro-Avila; Laura Jefferson; Veronica Dale; Karen Bloor
Journal:  BMJ Open       Date:  2021-05-11       Impact factor: 2.692

4.  Effect of vibration therapy on physical function in critically ill adults (VTICIA trial): protocol for a single-blinded randomised controlled trial.

Authors:  Nobuto Nakanishi; Satoshi Doi; Yoshimi Kawahara; Mie Shiraishi; Jun Oto
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

Review 5.  ICU-acquired weakness.

Authors:  Ilse Vanhorebeek; Nicola Latronico; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2020-02-19       Impact factor: 17.440

Review 6.  Urinary Titin N-Fragment as a Biomarker of Muscle Atrophy, Intensive Care Unit-Acquired Weakness, and Possible Application for Post-Intensive Care Syndrome.

Authors:  Nobuto Nakanishi; Rie Tsutsumi; Kanako Hara; Masafumi Matsuo; Hiroshi Sakaue; Jun Oto
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

Review 7.  Bedside voluntary and evoked forces evaluation in intensive care unit patients: a narrative review.

Authors:  Djahid Kennouche; Eric Luneau; Guillaume Y Millet; Julien Gondin; Thomas Lapole; Jérome Morel
Journal:  Crit Care       Date:  2021-04-22       Impact factor: 9.097

Review 8.  Intensive Care Unit-Acquired Weakness: A Review of Recent Progress With a Look Toward the Future.

Authors:  Wenkang Wang; Chuanjie Xu; Xinglong Ma; Xiaoming Zhang; Peng Xie
Journal:  Front Med (Lausanne)       Date:  2020-11-23

9.  Identification of the toxic threshold of 3-hydroxybutyrate-sodium supplementation in septic mice.

Authors:  Greet Van den Bergh; Lies Langouche; Ruben Weckx; Chloë Goossens; Sarah Derde; Lies Pauwels; Sarah Vander Perre
Journal:  BMC Pharmacol Toxicol       Date:  2021-09-20       Impact factor: 2.483

Review 10.  Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition.

Authors:  Heta Lad; Tyler M Saumur; Margaret S Herridge; Claudia C Dos Santos; Sunita Mathur; Jane Batt; Penney M Gilbert
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.